Talon Therapeutics Provides NDA Submission Timeline Update for Marqibo(R)
by on Thursday, June 30th, 2011 | No Comments
… primarily developing Marqibo for the treatment of adult, Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL). Vincristine, a microtubule inhibitor, is FDA-approved for ALL and is widely used as …
More here: Talon Therapeutics Provides NDA Submission Timeline Update for Marqibo(R)